肝功能损害患者临床药学服务模式的探索及效果评价

中国药物警戒 ›› 2018, Vol. 15 ›› Issue (5): 286-290.

肝功能损害患者临床药学服务模式的探索及效果评价

史秀梅,胡永领,梁艳丽,赵艳艳,王洁,谢士宁

徐州市传染病医院，江苏徐州221000

收稿日期:2018-01-19 修回日期:2018-06-21 出版日期:2018-05-20 发布日期:2018-06-21
作者简介:史秀梅，女，本科，副主任药师，临床药学。
基金资助:
2015年徐州市科技发展指导性计划项目（XZZDY1507）：肝功能损害患者临床药学服务模式的研究。

Clinical Pharmacy Service Mode and Its Effect on Patients with Liver Dysfunction

SHI Xiu-mei,HU Yong-ling, LIANG Yan-li,ZHAO Yan-yan,WANG Jie,XIE Shi-ning

Infectious Disease Hospital of Xuzhou,Jiangsu Xuzhou 000,China

Received:2018-01-19 Revised:2018-06-21 Online:2018-05-20 Published:2018-06-21
Contact: 胡永领,男,本科,副主任药师,医院药学。E-mail:15062110981@126.com

摘要/Abstract

摘要： 目的观察肝功能损害患者临床药学服务模式的效果，探索药学服务路径。方法选取我院2016年6月- 2017年5月收治的315例肝功能损害患者，按照患者入院时间，将2016年6月- 2016年11月158例入院者纳入对照组，将2016年12月- 2017年5月157名入院者纳入观察组。观察组患者根据Child-Turcotte-Pugh（CTP）评分对患者进行肝损害分级并给予规范临床药学服务，对照组仅接受常规药学服务，比较两组患者药物药效学、经济学、合理用药、药学服务效果等各项指标，总结临床药学服务模式的实施效果。结果观察组治疗总有效率为98.09%，高于对照组的89.87%；观察组的住院时间、住院总费用、保肝用药费用、用药总费用及用药总费用占住院费用比例均低于对照组，差异有统计学意义（P＜0.05），对照组ADR发生率为13.92%，高于观察组的6.37%；观察组药学服务知晓率、依从性、满意度均高于对照组，差异有统计学意义（P＜0.05）。结论规范化临床药学服务模式在提高肝功能损害患者治疗效果、降低治疗费用、保证合理用药、提高药学服务效果方面均具有积极意义，可予以优化与推广。

关键词: 肝功能损害, 药学服务模式, 合理用药, 临床药师

Abstract: Objective To observe the effects of clinical pharmacy service mode in patients with liver dysfunction, and to explore the pharmaceutical service method.Methods 315 cases of patients with liver injury in our hospital from June 2016 to May 2017 were included for this study. According to the time of admission,158 patients from June to November in 2016 were assigned to the control group, 157 patients from December 2016 to May 2017 were assigned to the observation group. Patients in the observation group received standardized clinical pharmacy service according to Child-Turcotte-Pugh (CTP) score, and the control group only received conventional pharmacy services. The indicators of pharmacodynamics, economics, rational use of drugs and pharmaceutical service effects were compared between the two groups, and the experience of clinical pharmacy service mode was summarized.Results The total efficacy of the observation group was 98.09%, which was higher than 89.87% of the control group. The hospitalization duration, the total hospitalization expenses, the cost of protecting the liver drug, the total cost of medication and the total cost of medication/total hospitalization expenses ratio in the observation group were lower than those in the control group, and the difference was statistically significant (P <0.05) .The incidence rate of ADR of control group was 13.92%, which was higher than 6.37% of the observation group. The pharmacy service awareness, compliance and satisfaction of observation group were higher than the control group, the difference was statistically significant (P <0.05).Conclusion For patients with liver function damage, the standardization of clinical pharmacy service mode can improve the treatment effects, reduce the cost of treatment, ensure the rational use of drugs and improve the effects of pharmaceutical care, which is worthy of optimization and promotion.

Key words: liver function damage, pharmaceutical service mode, rational drug use, clinical pharmacist

中图分类号:

史秀梅,胡永领,梁艳丽,赵艳艳,王洁,谢士宁 . 肝功能损害患者临床药学服务模式的探索及效果评价[J]. 中国药物警戒, 2018, 15(5): 286-290.

SHI Xiu-mei,HU Yong-ling, LIANG Yan-li,ZHAO Yan-yan,WANG Jie,XIE Shi-ning. Clinical Pharmacy Service Mode and Its Effect on Patients with Liver Dysfunction[J]. Chinese Journal of Pharmacovigilance, 2018, 15(5): 286-290.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/

https://zgywjj.magtechjournal.com/CN/Y2018/V15/I5/286

参考文献

[1] Fan X, Wang J, Xie L, et al. A new animal model for Polygonum multiflorum Thunb-induced liver injury in rats and its potential mechanisms[J]. Toxicology Research, 2015, 4(4): 1085-1097.
[2] 章超, 邹红, 康建华, 等. 1 例肺炎患者应用莫西沙星引起肝功能异常的药学监护[J]. 当代医学, 2016, 22(3): 82-83.
[3] Luo L, Yao Y T, Xue H, et al. Autologous hematopoietic stem cell transplantation in patients with end-stage liver disease: a 5-year follow-up study of 48 patients[J]. European review for medical and pharmacological sciences, 2016, 20(13): 2908-2915.
[4] Liu W, Li L, Xu J, et al. Pharmaceutical care for a patient with warfarin-induced autoimmune hepatitis[J].Journal of Peking University, 2016, 48(1): 183.
[5] Joost R, D rje F, Schwitulla J, et al. Intensified pharmaceutical care is improving immunosuppressive medication adherence in kidney transplant recipients during the first post-transplant year: a quasi-experimental study[J]. Nephrology Dialysis Transplantation, 2014, 29(8): 1597-1607.
[6] 王艳, 姬怀雪, 任玲. 亚急性甲状腺炎合并肝功能异常及高血压患者的药学监护[J]. 中国临床药理学杂志, 2015, 31(21): 2156-2157.
[7] Chen Y H, Kuo Z K, Cheng C M. Paper-a potential platform in pharmaceutical development[J]. Trends in biotechnology, 2015, 33(1): 4-9.
[8] Khalili H, Dashti-Khavidaki S, Rasoolinejad M, et al. Anti-tuberculosis drugs related hepatotoxicity; incidence, risk factors, pattern of changes in liver enzymes and outcome[J]. DARU Journal of Pharmaceutical Sciences, 2015, 17(3): 163-167.
[9] Wei L, Yang X, Li J, et al. Effect of pharmaceutical care on medication adherence and hospital admission in patients with chronic obstructive pulmonary disease (COPD): a randomized controlled study[J]. Journal of thoracic disease, 2014, 6(6): 656-662.
[10] 陈梦嘉, 应景艳, 徐爱仁, 等. 1 例妊娠甲状腺功能亢进综合征引起肝损伤的药学监护[J]. 中国现代应用药学, 2015, 32(4): 497-500.
[11] Peraman R, Palaian S, Izham M I M. Are doctor of pharmacy curricula in developing countries adequate to train graduates to provide pharmaceutical care?[J]. Archives of Pharmacy Practice, 2017, 8(1): 35.
[12] 骆丽芳, 戴海斌. 我国药学监护文献分析[J]. 中国医院药学杂志, 2017, 37(4):319-321.
[13] Klein A , Otto G, Kramer I. Impact of a pharmaceutical care program on liver transplant patients' compliance with immuno-suppressive medication: a prospective ， randomized ， controlled trial using electronic monitoring[J]. Transplantation, 2009, 87( 6 ): 839-847.
[14] Shah S, Dowell J, Greene S. Evaluation of clinical pharmacy services in a hematology/oncology outpatient setting[J]. Ann Pharmacother, 2006, 40(9)： 1527-1533.

[1]	柯秀琴, 海学武. 433例羟苯磺酸钙胶囊不良反应分析[J]. 中国药物警戒, 2025, 22(8): 924-927.
[2]	赵牡丹, 朱明辉, 张欢, 赵远洋, 秦靖. 1例彭氏变形杆菌致糖尿病足感染的药学监护[J]. 中国药物警戒, 2025, 22(8): 937-940.
[3]	郑斯莉, 张晓庆. 133例女性患者药品不良反应报告分析[J]. 中国药物警戒, 2025, 22(6): 654-658.
[4]	王浩, 马劲夫, 马瑞, 李晓刚, 赵强, 张弦. 注射用头孢哌酮舒巴坦钠致血小板减少1例分析[J]. 中国药物警戒, 2025, 22(6): 686-688.
[5]	梅丽平, 白福臣, 于杰, 张春杰, 王亚军, 安丽梅. 抗精神病药物血药浓度及其剂量比的影响因素[J]. 中国药物警戒, 2025, 22(4): 424-428.
[6]	邹远磊, 夏清荣, 梁俊, 何孔亮, 莫大明, 吴文宁. 抗抑郁药说明书警示语及预防措施分析[J]. 中国药物警戒, 2025, 22(3): 329-333.
[7]	周坤, 马良, 李肇丰, 曹斌, 顾洪伟, 刘茜. 某市精神卫生中心安神类中成药用药分析[J]. 中国药物警戒, 2025, 22(2): 211-216.
[8]	聂晓璐, 孙凤, 阎爱侠, 彭晓霞, 詹思延. 基于多源信息构建药品不良反应基准数据库[J]. 中国药物警戒, 2025, 22(1): 10-15.
[9]	刘楠楠, 席雅琳, 陈喆. 卡度尼利单抗致肾上腺皮质功能减退1例分析[J]. 中国药物警戒, 2025, 22(1): 109-112.
[10]	于玟路, 张虹. 马钱子在骨伤科的应用研究进展[J]. 中国药物警戒, 2025, 22(1): 116-120.
[11]	张彩霞, 周易, 谭璐, 陈文明, 柳阳, 游禹. 1例脓毒血症继发肺曲霉菌感染患者的药学监护[J]. 中国药物警戒, 2024, 21(9): 1064-1067.
[12]	张乾, 恽渊, 何恋. 1例利培酮致高泌乳素血症患者的药学监护[J]. 中国药物警戒, 2024, 21(8): 936-938.
[13]	阿拉腾花, 王振兴, 张晓朦, 世伟, 席成伟, 王聪慧, 王立群, 张冰. 基于药品不良反应监测数据的心脏器官伤害风险信号挖掘分析[J]. 中国药物警戒, 2024, 21(7): 752-758.
[14]	赵暄, 郑婷婷, 李雪梅, 毛璐, 郭婧, 张威. 万古霉素不良反应报告分析[J]. 中国药物警戒, 2024, 21(7): 811-815.
[15]	孙雪林, 杜娇, 谭琴, 胡欣, 张亚同, 郑丽. 阿美替尼上市后不良反应分析[J]. 中国药物警戒, 2024, 21(6): 683-686.